781 related articles for article (PubMed ID: 31685621)
1. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
3. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
4. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
[TBL] [Abstract][Full Text] [Related]
5. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
6. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
7. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
[TBL] [Abstract][Full Text] [Related]
8. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
[TBL] [Abstract][Full Text] [Related]
10. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
11. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
[TBL] [Abstract][Full Text] [Related]
12. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
Sensi M; Farina C; Maccalli C; Lupetti R; Nicolini G; Anichini A; Parmiani G; Berd D
J Clin Invest; 1997 Feb; 99(4):710-7. PubMed ID: 9045874
[TBL] [Abstract][Full Text] [Related]
13. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
14. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
15. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.
Nishimura MI; Kawakami Y; Charmley P; O'Neil B; Shilyansky J; Yannelli JR; Rosenberg SA; Hood L
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):85-94. PubMed ID: 7804531
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen-targeted CD8
Puig-Saus C; Sennino B; Peng S; Wang CL; Pan Z; Yuen B; Purandare B; An D; Quach BB; Nguyen D; Xia H; Jilani S; Shao K; McHugh C; Greer J; Peabody P; Nayak S; Hoover J; Said S; Jacoby K; Dalmas O; Foy SP; Conroy A; Yi MC; Shieh C; Lu W; Heeringa K; Ma Y; Chizari S; Pilling MJ; Ting M; Tunuguntla R; Sandoval S; Moot R; Hunter T; Zhao S; Saco JD; Perez-Garcilazo I; Medina E; Vega-Crespo A; Baselga-Carretero I; Abril-Rodriguez G; Cherry G; Wong DJ; Hundal J; Chmielowski B; Speiser DE; Bethune MT; Bao XR; Gros A; Griffith OL; Griffith M; Heath JR; Franzusoff A; Mandl SJ; Ribas A
Nature; 2023 Mar; 615(7953):697-704. PubMed ID: 36890230
[TBL] [Abstract][Full Text] [Related]
18. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
19. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
Peri A; Greenstein E; Alon M; Pai JA; Dingjan T; Reich-Zeliger S; Barnea E; Barbolin C; Levy R; Arnedo-Pac C; Kalaora S; Dassa B; Feldmesser E; Shang P; Greenberg P; Levin Y; Benedek G; Levesque MP; Adams DJ; Lotem M; Wilmott JS; Scolyer RA; Jönsson GB; Admon A; Rosenberg SA; Cohen CJ; Niv MY; Lopez-Bigas N; Satpathy AT; Friedman N; Samuels Y
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651586
[TBL] [Abstract][Full Text] [Related]
20. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
